Table 4.

Characteristics of Brincidofovir tested in preclinical studies (Outcome measures).

Ref.	Outcome Measures		Findings
Hutson, Kondas, Mauldin, Doty, Grossi, Morgan, Ostergaard, Hughes, Nakazawa, Kling, Martin, Ellison, Carroll, Gallardo-Romero and Olson [23]	Plasma concentration of BCV following single and repeat oral administration	Single oral administration	Median time of Tmax fell within 4–8 h range. The plasma concentration was below limit of quantification (BLQ) by 24 h for 5 mg/kg and by 36 h for 20 mg/kg.
		Repeat oral administration	Plasma concentration for predose prior to third administration were BLQ. Tmax is between 4–6 h. The plasma concentrations were BLQ on general by 24 h for 5 mg/kg and by 48 h for 20 mg/kg.
	Determining the efficacy of BVC in animals challenged with MPXV	Clinical signs	Vehicle group: appeared at day 5 post-infection in one animal & at day 8 post-infection for others. Clinical signs vary among animals. Animals receiving BCV (n = 7): Lowest average maximum clinical score recorded Other animals: Have scores of 8.1 (those received treatment on the day of infection), 8.7 (those received BCV 1 day p.i) and 9.1 (those in vehicle group)
		Mortality	Varying survival rate calculated for different groups: 57% (those received treatment 1 day prior infection), 43% (those received treatment on day of infection), 29% (those received BCV 1 day p.i.) and 14% (vehicle group) Animals receiving BCV before challenge had shown to have delay in mortality.